Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Terheyden

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|September 6, 2016
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialHoward L Kaufman, Jeffery Russell, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, et al.
Oncotarget|November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trialSelma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k-Leitlinie - Merkelzellkarzinom - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 3, 2024
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patientsInga Hansen-Abeck, Glenn Geidel, Finn Abeck, et al.
Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanomaElias A T Koch, Anne Petzold, Anja Wessely, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|September 6, 2016
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialHoward L Kaufman, Jeffery Russell, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, et al.
Oncotarget|November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trialSelma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Frontiers in Immunology|June 21, 2024
Clinical and genetic characteristics of <i>BAP1</i>-mutated non-uveal and uveal melanomaJohanna Matull, Jan-Malte Placke, Georg Lodde, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k-Leitlinie - Merkelzellkarzinom - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 3, 2024
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patientsInga Hansen-Abeck, Glenn Geidel, Finn Abeck, et al.
Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanomaElias A T Koch, Anne Petzold, Anja Wessely, et al.
Pageof 13